Epitizide

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Epitizide
Accession Number
DB13989
Type
Small Molecule
Groups
Experimental
Description

Epitizide is a diuretic. It is often combined with triamterene.

Structure
Thumb
Synonyms
  • Epithiazide
  • Epitizidum
  • Eptizida
External IDs
P 2105 / P-2105
Categories
UNII
5B266B85J1
CAS number
1764-85-8
Weight
Average: 425.84
Monoisotopic: 424.9552316
Chemical Formula
C10H11ClF3N3O4S3
InChI Key
RINBGYCKMGDWPY-UHFFFAOYSA-N
InChI
InChI=1S/C10H11ClF3N3O4S3/c11-5-1-6-8(2-7(5)23(15,18)19)24(20,21)17-9(16-6)3-22-4-10(12,13)14/h1-2,9,16-17H,3-4H2,(H2,15,18,19)
IUPAC Name
6-chloro-1,1-dioxo-3-{[(2,2,2-trifluoroethyl)sulfanyl]methyl}-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide
SMILES
NS(=O)(=O)C1=CC2=C(NC(CSCC(F)(F)F)NS2(=O)=O)C=C1Cl

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe therapeutic efficacy of Epitizide can be decreased when used in combination with (4R)-limonene.Investigational
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the hypokalemic activities of Epitizide.Investigational
19-norandrostenedione19-norandrostenedione may increase the hypokalemic activities of Epitizide.Experimental, Illicit
1alpha-Hydroxyvitamin D5The risk or severity of hyperkalemia can be increased when 1alpha-Hydroxyvitamin D5 is combined with Epitizide.Investigational
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Epitizide.Investigational
5-androstenedione5-androstenedione may increase the hypokalemic activities of Epitizide.Experimental, Illicit
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Epitizide.Approved, Investigational
AceclofenacThe therapeutic efficacy of Epitizide can be decreased when used in combination with Aceclofenac.Approved, Investigational
AcemetacinThe therapeutic efficacy of Epitizide can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Epitizide.Approved, Investigational, Withdrawn
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Epitizide is combined with Acetyldigitoxin.Approved
AcetyldigoxinThe risk or severity of adverse effects can be increased when Epitizide is combined with Acetyldigoxin.Experimental
Acetylsalicylic acidThe therapeutic efficacy of Epitizide can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AclidiniumThe serum concentration of Epitizide can be increased when it is combined with Aclidinium.Approved
AdapaleneThe therapeutic efficacy of Epitizide can be decreased when used in combination with Adapalene.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Epitizide.Experimental, Investigational
AlaproclateAlaproclate may increase the hyponatremic activities of Epitizide.Experimental
AlclofenacThe therapeutic efficacy of Epitizide can be decreased when used in combination with Alclofenac.Approved, Withdrawn
AlclometasoneAlclometasone may increase the hypokalemic activities of Epitizide.Approved
AlcuroniumThe serum concentration of Epitizide can be increased when it is combined with Alcuronium.Experimental
AldosteroneAldosterone may increase the hypokalemic activities of Epitizide.Experimental, Investigational
AlfacalcidolThe risk or severity of hyperkalemia can be increased when Alfacalcidol is combined with Epitizide.Approved, Nutraceutical
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Epitizide.Approved, Illicit
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Epitizide.Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Epitizide.Approved
AlminoprofenThe therapeutic efficacy of Epitizide can be decreased when used in combination with Alminoprofen.Experimental
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Epitizide.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Epitizide.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Epitizide.Illicit
AmcinonideAmcinonide may increase the hypokalemic activities of Epitizide.Approved
AmobarbitalAmobarbital may increase the orthostatic hypotensive activities of Epitizide.Approved, Illicit
AndrographolideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Andrographolide.Investigational
AndrostenedioneAndrostenedione may increase the hypokalemic activities of Epitizide.Experimental, Illicit
AnecortaveAnecortave may increase the hypokalemic activities of Epitizide.Investigational
anecortave acetateanecortave acetate may increase the hypokalemic activities of Epitizide.Investigational
AnisodamineThe therapeutic efficacy of Epitizide can be decreased when used in combination with Anisodamine.Investigational
Anisotropine MethylbromideThe serum concentration of Epitizide can be increased when it is combined with Anisotropine Methylbromide.Approved
AntipyrineThe therapeutic efficacy of Epitizide can be decreased when used in combination with Antipyrine.Approved, Investigational
ApocyninThe therapeutic efficacy of Epitizide can be decreased when used in combination with Apocynin.Investigational
ApremilastThe therapeutic efficacy of Epitizide can be decreased when used in combination with Apremilast.Approved, Investigational
ArbutamineArbutamine may increase the hypokalemic activities of Epitizide.Approved
ArformoterolArformoterol may increase the hypokalemic activities of Epitizide.Approved, Investigational
AtamestaneAtamestane may increase the hypokalemic activities of Epitizide.Investigational
AtracuriumThe serum concentration of Epitizide can be increased when it is combined with Atracurium.Approved, Experimental, Investigational
Atracurium besylateThe serum concentration of Epitizide can be increased when it is combined with Atracurium besylate.Approved
AtropineThe serum concentration of Epitizide can be increased when it is combined with Atropine.Approved, Vet Approved
AzapropazoneThe therapeutic efficacy of Epitizide can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Epitizide can be decreased when used in combination with Azelastine.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Epitizide.Investigational
BalsalazideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Balsalazide.Approved, Investigational
BambuterolBambuterol may increase the hypokalemic activities of Epitizide.Approved, Investigational
BarbexacloneBarbexaclone may increase the orthostatic hypotensive activities of Epitizide.Experimental
BarbitalBarbital may increase the orthostatic hypotensive activities of Epitizide.Illicit
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Epitizide.Approved, Investigational
BecocalcidiolThe risk or severity of hyperkalemia can be increased when Becocalcidiol is combined with Epitizide.Investigational
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Epitizide.Investigational
BenactyzineThe serum concentration of Epitizide can be increased when it is combined with Benactyzine.Withdrawn
BenazeprilThe risk or severity of hypotension can be increased when Epitizide is combined with Benazepril.Approved, Investigational
BendazacThe therapeutic efficacy of Epitizide can be decreased when used in combination with Bendazac.Experimental
BenorilateThe therapeutic efficacy of Epitizide can be decreased when used in combination with Benorilate.Experimental
BenoxaprofenThe therapeutic efficacy of Epitizide can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzatropineThe serum concentration of Epitizide can be increased when it is combined with Benzatropine.Approved
BenzydamineThe therapeutic efficacy of Epitizide can be decreased when used in combination with Benzydamine.Approved
BetamethasoneBetamethasone may increase the hypokalemic activities of Epitizide.Approved, Vet Approved
BevoniumThe therapeutic efficacy of Epitizide can be decreased when used in combination with Bevonium.Experimental
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Epitizide.Experimental, Illicit, Withdrawn
BiperidenThe serum concentration of Epitizide can be increased when it is combined with Biperiden.Approved, Investigational
BornaprineThe serum concentration of Epitizide can be increased when it is combined with Bornaprine.Experimental
BromfenacThe therapeutic efficacy of Epitizide can be decreased when used in combination with Bromfenac.Approved
BucillamineThe therapeutic efficacy of Epitizide can be decreased when used in combination with Bucillamine.Investigational
BudesonideBudesonide may increase the hypokalemic activities of Epitizide.Approved
BufexamacThe therapeutic efficacy of Epitizide can be decreased when used in combination with Bufexamac.Approved, Experimental
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Epitizide.Investigational, Withdrawn
BumadizoneThe therapeutic efficacy of Epitizide can be decreased when used in combination with Bumadizone.Experimental
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Epitizide.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Epitizide.Approved, Illicit, Vet Approved
ButylscopolamineThe serum concentration of Epitizide can be increased when it is combined with Butylscopolamine.Approved, Investigational, Vet Approved
CalcidiolThe risk or severity of hyperkalemia can be increased when Calcidiol is combined with Epitizide.Approved, Nutraceutical
CalcipotriolThe risk or severity of hyperkalemia can be increased when Calcipotriol is combined with Epitizide.Approved
CalcitriolThe risk or severity of hyperkalemia can be increased when Calcitriol is combined with Epitizide.Approved, Nutraceutical
Calcium AcetateEpitizide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved, Investigational
Calcium ChlorideEpitizide may decrease the excretion rate of Calcium Chloride which could result in a higher serum level.Approved
Calcium CitrateEpitizide may decrease the excretion rate of Calcium Citrate which could result in a higher serum level.Approved
Calcium glubionateEpitizide may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.Approved
Calcium GluceptateEpitizide may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level.Approved
Calcium gluconateEpitizide may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.Approved, Vet Approved
Calcium lactateEpitizide may decrease the excretion rate of Calcium lactate which could result in a higher serum level.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateEpitizide may decrease the excretion rate of Calcium lactate gluconate which could result in a higher serum level.Experimental
Calcium levulinateEpitizide may decrease the excretion rate of Calcium levulinate which could result in a higher serum level.Approved, Experimental
Calcium pangamateEpitizide may decrease the excretion rate of Calcium pangamate which could result in a higher serum level.Experimental
Calcium PhosphateEpitizide may decrease the excretion rate of Calcium Phosphate which could result in a higher serum level.Approved
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Epitizide.Approved
Candesartan cilexetilThe risk or severity of hypotension can be increased when Candesartan cilexetil is combined with Epitizide.Approved
CandoxatrilThe risk or severity of hypotension can be increased when Epitizide is combined with Candoxatril.Experimental
CaptoprilThe risk or severity of hypotension can be increased when Epitizide is combined with Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Epitizide is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe therapeutic efficacy of Epitizide can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Epitizide.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Epitizide.Illicit, Investigational, Vet Approved
CarprofenThe therapeutic efficacy of Epitizide can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CaseinEpitizide may decrease the excretion rate of Casein which could result in a higher serum level.Approved
CastanospermineThe therapeutic efficacy of Epitizide can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Epitizide can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypokalemic activities of Epitizide.Approved, Investigational
ChloroquineThe therapeutic efficacy of Epitizide can be decreased when used in combination with Chloroquine.Approved, Investigational, Vet Approved
ChlorphenoxamineThe serum concentration of Epitizide can be increased when it is combined with Chlorphenoxamine.Withdrawn
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Epitizide.Approved, Investigational
CholecalciferolThe risk or severity of hyperkalemia can be increased when Cholecalciferol is combined with Epitizide.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Epitizide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe therapeutic efficacy of Epitizide can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CiclesonideCiclesonide may increase the hypokalemic activities of Epitizide.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Epitizide.Experimental
CilazaprilThe risk or severity of hypotension can be increased when Epitizide is combined with Cilazapril.Approved
CitalopramCitalopram may increase the hyponatremic activities of Epitizide.Approved
ClenbuterolClenbuterol may increase the hypokalemic activities of Epitizide.Approved, Investigational, Vet Approved
ClobetasolClobetasol may increase the hypokalemic activities of Epitizide.Approved, Investigational
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Epitizide.Approved
ClobetasoneClobetasone may increase the hypokalemic activities of Epitizide.Approved
ClocortoloneClocortolone may increase the hypokalemic activities of Epitizide.Approved
ClonixinThe therapeutic efficacy of Epitizide can be decreased when used in combination with Clonixin.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Epitizide.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Epitizide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Epitizide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateCortexolone 17α-propionate may increase the hypokalemic activities of Epitizide.Investigational
CorticosteroneCorticosterone may increase the hypokalemic activities of Epitizide.Experimental
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Epitizide.Approved, Investigational
CurcuminThe therapeutic efficacy of Epitizide can be decreased when used in combination with Curcumin.Approved, Investigational
CyclopentolateThe serum concentration of Epitizide can be increased when it is combined with Cyclopentolate.Approved
CyclophosphamideThe risk or severity of severe leukopenia can be increased when Epitizide is combined with Cyclophosphamide.Approved, Investigational
CymarinThe risk or severity of adverse effects can be increased when Epitizide is combined with Cymarin.Experimental
DapoxetineDapoxetine may increase the hyponatremic activities of Epitizide.Investigational
DarifenacinThe serum concentration of Epitizide can be increased when it is combined with Darifenacin.Approved, Investigational
DeflazacortDeflazacort may increase the hypokalemic activities of Epitizide.Approved, Investigational
DelaprilThe risk or severity of hypotension can be increased when Epitizide is combined with Delapril.Experimental
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Epitizide.Investigational
DeslanosideThe risk or severity of adverse effects can be increased when Epitizide is combined with Deslanoside.Approved
DesloratadineThe serum concentration of Epitizide can be increased when it is combined with Desloratadine.Approved, Investigational
DesonideDesonide may increase the hypokalemic activities of Epitizide.Approved, Investigational
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Epitizide.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Epitizide.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the hypokalemic activities of Epitizide.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the hyponatremic activities of Epitizide.Approved, Investigational
DexamethasoneDexamethasone may increase the hypokalemic activities of Epitizide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Epitizide.Vet Approved
DexetimideThe serum concentration of Epitizide can be increased when it is combined with Dexetimide.Withdrawn
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Epitizide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Epitizide.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Epitizide.Approved, Investigational
DiazoxideThe risk or severity of adverse effects can be increased when Epitizide is combined with Diazoxide.Approved
DiclofenacThe therapeutic efficacy of Epitizide can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DicyclomineThe serum concentration of Epitizide can be increased when it is combined with Dicyclomine.Approved
DifenpiramideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Difenpiramide.Experimental
DiflorasoneDiflorasone may increase the hypokalemic activities of Epitizide.Approved
DiflunisalThe therapeutic efficacy of Epitizide can be decreased when used in combination with Diflunisal.Approved, Investigational
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Epitizide.Approved, Investigational, Withdrawn
DifluprednateDifluprednate may increase the hypokalemic activities of Epitizide.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Epitizide is combined with Digitoxin.Approved, Investigational
DigoxinThe risk or severity of adverse effects can be increased when Epitizide is combined with Digoxin.Approved
Digoxin Immune Fab (Ovine)The risk or severity of adverse effects can be increased when Epitizide is combined with Digoxin Immune Fab (Ovine).Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Epitizide.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Epitizide.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Epitizide.Experimental, Illicit
DihydrotachysterolThe risk or severity of hyperkalemia can be increased when Dihydrotachysterol is combined with Epitizide.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Epitizide.Approved, Illicit
DipivefrinDipivefrin may increase the hypokalemic activities of Epitizide.Approved
DobutamineDobutamine may increase the hypokalemic activities of Epitizide.Approved
DofetilideEpitizide may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
DoxercalciferolThe risk or severity of hyperkalemia can be increased when Doxercalciferol is combined with Epitizide.Approved
DoxofyllineDoxofylline may increase the hypokalemic activities of Epitizide.Approved, Investigational
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Epitizide.Experimental
DroxicamThe therapeutic efficacy of Epitizide can be decreased when used in combination with Droxicam.Withdrawn
DroxidopaDroxidopa may increase the hypokalemic activities of Epitizide.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Epitizide.Approved, Investigational
DuloxetineDuloxetine may increase the hyponatremic activities of Epitizide.Approved
DuvelisibThe therapeutic efficacy of Epitizide can be decreased when used in combination with Duvelisib.Investigational
E-6201The therapeutic efficacy of Epitizide can be decreased when used in combination with E-6201.Investigational
EldecalcitolThe risk or severity of hyperkalemia can be increased when Eldecalcitol is combined with Epitizide.Investigational
ElocalcitolThe risk or severity of hyperkalemia can be increased when Elocalcitol is combined with Epitizide.Investigational
EmeproniumThe serum concentration of Epitizide can be increased when it is combined with Emepronium.Experimental
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Epitizide.Approved
EnalaprilThe risk or severity of hypotension can be increased when Epitizide is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of hypotension can be increased when Epitizide is combined with Enalaprilat.Approved
EphedraEphedra may increase the hypokalemic activities of Epitizide.Approved, Nutraceutical, Withdrawn
EpinephrineEpinephrine may increase the hypokalemic activities of Epitizide.Approved, Vet Approved
EpirizoleThe therapeutic efficacy of Epitizide can be decreased when used in combination with Epirizole.Approved
EquileninEquilenin may increase the hypokalemic activities of Epitizide.Experimental
EquilinEquilin may increase the hypokalemic activities of Epitizide.Approved
ErgocalciferolThe risk or severity of hyperkalemia can be increased when Ergocalciferol is combined with Epitizide.Approved, Nutraceutical
EscitalopramEscitalopram may increase the hyponatremic activities of Epitizide.Approved, Investigational
EstroneEstrone may increase the hypokalemic activities of Epitizide.Approved
Estrone sulfateEstrone sulfate may increase the hypokalemic activities of Epitizide.Approved
EtanautineThe serum concentration of Epitizide can be increased when it is combined with Etanautine.Experimental
EtanerceptThe therapeutic efficacy of Epitizide can be decreased when used in combination with Etanercept.Approved, Investigational
EthanolEthanol may increase the orthostatic hypotensive activities of Epitizide.Approved
EthenzamideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Ethenzamide.Experimental
EthopropazineThe serum concentration of Epitizide can be increased when it is combined with Ethopropazine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Epitizide.Approved, Illicit
EtodolacThe therapeutic efficacy of Epitizide can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Epitizide can be decreased when used in combination with Etofenamate.Approved, Investigational
EtoperidoneEtoperidone may increase the hyponatremic activities of Epitizide.Withdrawn
EtoricoxibThe therapeutic efficacy of Epitizide can be decreased when used in combination with Etoricoxib.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Epitizide.Illicit, Vet Approved
EtybenzatropineThe serum concentration of Epitizide can be increased when it is combined with Etybenzatropine.Experimental
Evening primrose oilThe therapeutic efficacy of Epitizide can be decreased when used in combination with Evening primrose oil.Approved, Investigational
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Epitizide.Approved, Investigational
ExisulindThe therapeutic efficacy of Epitizide can be decreased when used in combination with Exisulind.Investigational
FelbinacThe therapeutic efficacy of Epitizide can be decreased when used in combination with Felbinac.Experimental
FenbufenThe therapeutic efficacy of Epitizide can be decreased when used in combination with Fenbufen.Approved
FenoprofenThe therapeutic efficacy of Epitizide can be decreased when used in combination with Fenoprofen.Approved
FenoterolFenoterol may increase the hypokalemic activities of Epitizide.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Epitizide.Approved, Illicit, Investigational, Vet Approved
FentiazacThe therapeutic efficacy of Epitizide can be decreased when used in combination with Fentiazac.Experimental
FeprazoneThe therapeutic efficacy of Epitizide can be decreased when used in combination with Feprazone.Experimental
Ferulic acidThe therapeutic efficacy of Epitizide can be decreased when used in combination with Ferulic acid.Experimental
FesoterodineThe serum concentration of Epitizide can be increased when it is combined with Fesoterodine.Approved
FloctafenineThe therapeutic efficacy of Epitizide can be decreased when used in combination with Floctafenine.Approved, Withdrawn
FluasteroneFluasterone may increase the hypokalemic activities of Epitizide.Investigational
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Epitizide.Approved, Investigational
FlumethasoneFlumethasone may increase the hypokalemic activities of Epitizide.Approved, Vet Approved
FlunisolideFlunisolide may increase the hypokalemic activities of Epitizide.Approved, Investigational
FlunixinThe therapeutic efficacy of Epitizide can be decreased when used in combination with Flunixin.Vet Approved
FlunoxaprofenThe therapeutic efficacy of Epitizide can be decreased when used in combination with Flunoxaprofen.Experimental
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Epitizide.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hypokalemic activities of Epitizide.Approved, Investigational
FluocortoloneFluocortolone may increase the hypokalemic activities of Epitizide.Approved, Withdrawn
FluorometholoneFluorometholone may increase the hypokalemic activities of Epitizide.Approved, Investigational
FluoxetineFluoxetine may increase the hyponatremic activities of Epitizide.Approved, Vet Approved
FluprednideneFluprednidene may increase the hypokalemic activities of Epitizide.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Epitizide.Approved
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Epitizide.Approved
FlurbiprofenThe therapeutic efficacy of Epitizide can be decreased when used in combination with Flurbiprofen.Approved, Investigational
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Epitizide.Approved
Fluticasone propionateFluticasone propionate may increase the hypokalemic activities of Epitizide.Approved
FluvoxamineFluvoxamine may increase the hyponatremic activities of Epitizide.Approved, Investigational
FormestaneFormestane may increase the hypokalemic activities of Epitizide.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the hypokalemic activities of Epitizide.Approved, Investigational
FosinoprilThe risk or severity of hypotension can be increased when Epitizide is combined with Fosinopril.Approved
GallamineThe serum concentration of Epitizide can be increased when it is combined with Gallamine.Experimental
Gallamine TriethiodideThe serum concentration of Epitizide can be increased when it is combined with Gallamine Triethiodide.Approved
GitoformateThe risk or severity of adverse effects can be increased when Epitizide is combined with Gitoformate.Experimental
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Epitizide.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Epitizide.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Epitizide.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Epitizide.Approved, Investigational
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Epitizide.Approved, Investigational
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Epitizide.Approved
GlycopyrroniumThe serum concentration of Epitizide can be increased when it is combined with Glycopyrronium.Approved, Investigational, Vet Approved
GuacetisalThe therapeutic efficacy of Epitizide can be decreased when used in combination with Guacetisal.Experimental
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Epitizide.Investigational
HalcinonideHalcinonide may increase the hypokalemic activities of Epitizide.Approved, Investigational, Withdrawn
HE3286HE3286 may increase the hypokalemic activities of Epitizide.Investigational
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Epitizide.Approved, Illicit, Investigational
HexamethoniumThe serum concentration of Epitizide can be increased when it is combined with Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the orthostatic hypotensive activities of Epitizide.Approved
HigenamineThe therapeutic efficacy of Epitizide can be decreased when used in combination with Higenamine.Investigational
HomatropineThe serum concentration of Epitizide can be increased when it is combined with Homatropine.Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Epitizide.Approved, Illicit
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Epitizide.Approved, Vet Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Epitizide.Approved, Illicit
HyoscyamineThe serum concentration of Epitizide can be increased when it is combined with Hyoscyamine.Approved
IbuprofenThe therapeutic efficacy of Epitizide can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Epitizide can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Epitizide can be decreased when used in combination with Icatibant.Approved, Investigational
ImidaprilThe risk or severity of hypotension can be increased when Epitizide is combined with Imidapril.Investigational
Imidazole salicylateThe therapeutic efficacy of Epitizide can be decreased when used in combination with Imidazole salicylate.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Epitizide.Approved
IndalpineIndalpine may increase the hyponatremic activities of Epitizide.Investigational, Withdrawn
IndobufenThe therapeutic efficacy of Epitizide can be decreased when used in combination with Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Epitizide can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Epitizide can be decreased when used in combination with Indoprofen.Withdrawn
InecalcitolThe risk or severity of hyperkalemia can be increased when Inecalcitol is combined with Epitizide.Experimental, Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Epitizide.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Epitizide.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Epitizide.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Epitizide.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Epitizide.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Epitizide.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Epitizide.Approved
Ipratropium bromideThe serum concentration of Epitizide can be increased when it is combined with Ipratropium bromide.Approved
IsoetarineIsoetarine may increase the hypokalemic activities of Epitizide.Approved
IsoprenalineIsoprenaline may increase the hypokalemic activities of Epitizide.Approved, Investigational
IsoxicamThe therapeutic efficacy of Epitizide can be decreased when used in combination with Isoxicam.Withdrawn
IstaroximeIstaroxime may increase the hypokalemic activities of Epitizide.Investigational
IvabradineEpitizide may increase the arrhythmogenic activities of Ivabradine.Approved
KebuzoneThe therapeutic efficacy of Epitizide can be decreased when used in combination with Kebuzone.Experimental
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Epitizide.Approved, Investigational
KetoprofenThe therapeutic efficacy of Epitizide can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Epitizide can be decreased when used in combination with Ketorolac.Approved
Lanatoside CThe risk or severity of adverse effects can be increased when Epitizide is combined with Lanatoside C.Experimental
LeflunomideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Leflunomide.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Epitizide.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the hyponatremic activities of Epitizide.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Epitizide.Approved
LevosalbutamolLevosalbutamol may increase the hypokalemic activities of Epitizide.Approved, Investigational
LicoriceLicorice may increase the hypokalemic activities of Epitizide.Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Epitizide.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Epitizide.Approved
LisinoprilThe risk or severity of hypotension can be increased when Epitizide is combined with Lisinopril.Approved, Investigational
LisofyllineThe therapeutic efficacy of Epitizide can be decreased when used in combination with Lisofylline.Investigational
LithiumEpitizide may decrease the excretion rate of Lithium which could result in a higher serum level.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Epitizide.Illicit
LonazolacThe therapeutic efficacy of Epitizide can be decreased when used in combination with Lonazolac.Experimental
LornoxicamThe therapeutic efficacy of Epitizide can be decreased when used in combination with Lornoxicam.Approved, Investigational
LoteprednolLoteprednol may increase the hypokalemic activities of Epitizide.Approved
LoxoprofenThe therapeutic efficacy of Epitizide can be decreased when used in combination with Loxoprofen.Approved, Investigational
LumiracoxibThe therapeutic efficacy of Epitizide can be decreased when used in combination with Lumiracoxib.Approved, Investigational
Magnesium salicylateThe therapeutic efficacy of Epitizide can be decreased when used in combination with Magnesium salicylate.Approved
MasoprocolThe therapeutic efficacy of Epitizide can be decreased when used in combination with Masoprocol.Approved, Investigational
MaxacalcitolThe risk or severity of hyperkalemia can be increased when Maxacalcitol is combined with Epitizide.Approved, Investigational
MazaticolThe serum concentration of Epitizide can be increased when it is combined with Mazaticol.Experimental
ME-609ME-609 may increase the hypokalemic activities of Epitizide.Investigational
MecamylamineThe serum concentration of Epitizide can be increased when it is combined with Mecamylamine.Approved, Investigational
Meclofenamic acidThe therapeutic efficacy of Epitizide can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
MedrysoneMedrysone may increase the hypokalemic activities of Epitizide.Approved
Mefenamic acidThe therapeutic efficacy of Epitizide can be decreased when used in combination with Mefenamic acid.Approved
MelengestrolMelengestrol may increase the hypokalemic activities of Epitizide.Vet Approved
MeloxicamThe therapeutic efficacy of Epitizide can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Epitizide.Experimental
MesalazineThe therapeutic efficacy of Epitizide can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Epitizide can be decreased when used in combination with Metamizole.Approved, Investigational, Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Epitizide.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Epitizide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Epitizide.Approved, Illicit
MethanthelineThe serum concentration of Epitizide can be increased when it is combined with Methantheline.Approved, Investigational
MethohexitalMethohexital may increase the orthostatic hypotensive activities of Epitizide.Approved
MethylphenobarbitalMethylphenobarbital may increase the orthostatic hypotensive activities of Epitizide.Approved
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Epitizide.Approved, Vet Approved
Methylscopolamine bromideThe serum concentration of Epitizide can be increased when it is combined with Methylscopolamine bromide.Approved
MetildigoxinThe risk or severity of adverse effects can be increased when Epitizide is combined with Metildigoxin.Experimental
MetixeneThe serum concentration of Epitizide can be increased when it is combined with Metixene.Approved
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Epitizide.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Epitizide.Approved
MilnacipranMilnacipran may increase the hyponatremic activities of Epitizide.Approved, Investigational
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Epitizide.Approved, Investigational
MizoribineThe therapeutic efficacy of Epitizide can be decreased when used in combination with Mizoribine.Investigational
MoexiprilThe risk or severity of hypotension can be increased when Epitizide is combined with Moexipril.Approved
MofebutazoneThe therapeutic efficacy of Epitizide can be decreased when used in combination with Mofebutazone.Experimental
MometasoneMometasone may increase the hypokalemic activities of Epitizide.Approved, Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Epitizide.Approved, Investigational
Mycophenolate mofetilThe therapeutic efficacy of Epitizide can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Epitizide can be decreased when used in combination with Mycophenolic acid.Approved
NabumetoneThe therapeutic efficacy of Epitizide can be decreased when used in combination with Nabumetone.Approved
NafamostatThe therapeutic efficacy of Epitizide can be decreased when used in combination with Nafamostat.Approved, Investigational
NaftifineThe therapeutic efficacy of Epitizide can be decreased when used in combination with Naftifine.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Epitizide.Approved
NaproxenThe therapeutic efficacy of Epitizide can be decreased when used in combination with Naproxen.Approved, Vet Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Epitizide.Approved, Investigational
NCX 1022NCX 1022 may increase the hypokalemic activities of Epitizide.Investigational
NefazodoneNefazodone may increase the hyponatremic activities of Epitizide.Approved, Withdrawn
NepafenacThe therapeutic efficacy of Epitizide can be decreased when used in combination with Nepafenac.Approved, Investigational
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Epitizide.Experimental
NifenazoneThe therapeutic efficacy of Epitizide can be decreased when used in combination with Nifenazone.Experimental
Niflumic AcidThe therapeutic efficacy of Epitizide can be decreased when used in combination with Niflumic Acid.Approved
NimesulideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe therapeutic efficacy of Epitizide can be decreased when used in combination with Nitroaspirin.Investigational
NorepinephrineNorepinephrine may increase the hypokalemic activities of Epitizide.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Epitizide.Approved, Illicit
OleandrinThe risk or severity of adverse effects can be increased when Epitizide is combined with Oleandrin.Experimental, Investigational
Oleoyl-estroneOleoyl-estrone may increase the hypokalemic activities of Epitizide.Investigational
OlodaterolOlodaterol may increase the hypokalemic activities of Epitizide.Approved
OlopatadineThe therapeutic efficacy of Epitizide can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Epitizide can be decreased when used in combination with Olsalazine.Approved
OmapatrilatThe risk or severity of hypotension can be increased when Epitizide is combined with Omapatrilat.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Epitizide.Approved, Illicit
OrciprenalineOrciprenaline may increase the hypokalemic activities of Epitizide.Approved
OrgoteinThe therapeutic efficacy of Epitizide can be decreased when used in combination with Orgotein.Vet Approved
OrphenadrineThe serum concentration of Epitizide can be increased when it is combined with Orphenadrine.Approved
OtiloniumThe serum concentration of Epitizide can be increased when it is combined with Otilonium.Experimental, Investigational
OuabainThe risk or severity of adverse effects can be increased when Epitizide is combined with Ouabain.Approved
OxaprozinThe therapeutic efficacy of Epitizide can be decreased when used in combination with Oxaprozin.Approved
OxcarbazepineThe risk or severity of hyponatremia can be increased when Epitizide is combined with Oxcarbazepine.Approved
OxitropiumThe serum concentration of Epitizide can be increased when it is combined with Oxitropium.Investigational
OxybutyninThe serum concentration of Epitizide can be increased when it is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Epitizide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Epitizide.Approved, Investigational, Vet Approved
OxyphenbutazoneThe therapeutic efficacy of Epitizide can be decreased when used in combination with Oxyphenbutazone.Approved, Withdrawn
OxyphenoniumThe serum concentration of Epitizide can be increased when it is combined with Oxyphenonium.Approved
PancuroniumThe serum concentration of Epitizide can be increased when it is combined with Pancuronium.Approved
ParamethasoneParamethasone may increase the hypokalemic activities of Epitizide.Approved
ParecoxibThe therapeutic efficacy of Epitizide can be decreased when used in combination with Parecoxib.Approved
ParicalcitolThe risk or severity of hyperkalemia can be increased when Paricalcitol is combined with Epitizide.Approved, Investigational
ParoxetineParoxetine may increase the hyponatremic activities of Epitizide.Approved, Investigational
ParthenolideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Parthenolide.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Epitizide.Approved, Vet Approved
PentobarbitalPentobarbital may increase the orthostatic hypotensive activities of Epitizide.Approved, Investigational, Vet Approved
PentoliniumThe serum concentration of Epitizide can be increased when it is combined with Pentolinium.Approved
PerindoprilThe risk or severity of hypotension can be increased when Epitizide is combined with Perindopril.Approved
PeruvosideThe risk or severity of adverse effects can be increased when Epitizide is combined with Peruvoside.Experimental
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Epitizide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Epitizide.Experimental
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Epitizide.Approved, Investigational, Withdrawn
PhenglutarimideThe serum concentration of Epitizide can be increased when it is combined with Phenglutarimide.Experimental
PhenobarbitalPhenobarbital may increase the orthostatic hypotensive activities of Epitizide.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Epitizide.Experimental
PhenylbutazoneThe therapeutic efficacy of Epitizide can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Epitizide.Approved, Vet Approved, Withdrawn
PimecrolimusThe therapeutic efficacy of Epitizide can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Epitizide.Approved, Investigational
PipecuroniumThe serum concentration of Epitizide can be increased when it is combined with Pipecuronium.Approved
PirbuterolPirbuterol may increase the hypokalemic activities of Epitizide.Approved
PirenzepineThe serum concentration of Epitizide can be increased when it is combined with Pirenzepine.Approved
PirfenidoneThe therapeutic efficacy of Epitizide can be decreased when used in combination with Pirfenidone.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Epitizide.Approved, Investigational
PiroxicamThe therapeutic efficacy of Epitizide can be decreased when used in combination with Piroxicam.Approved, Investigational
PirprofenThe therapeutic efficacy of Epitizide can be decreased when used in combination with Pirprofen.Experimental
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Epitizide.Approved, Investigational
PranoprofenThe therapeutic efficacy of Epitizide can be decreased when used in combination with Pranoprofen.Experimental, Investigational
PrasteronePrasterone may increase the hypokalemic activities of Epitizide.Approved, Investigational, Nutraceutical
Prasterone sulfatePrasterone sulfate may increase the hypokalemic activities of Epitizide.Investigational
PrednicarbatePrednicarbate may increase the hypokalemic activities of Epitizide.Approved, Investigational
PrednisolonePrednisolone may increase the hypokalemic activities of Epitizide.Approved, Vet Approved
PrednisonePrednisone may increase the hypokalemic activities of Epitizide.Approved, Vet Approved
PregnenolonePregnenolone may increase the hypokalemic activities of Epitizide.Approved, Experimental, Investigational
PrimidonePrimidone may increase the orthostatic hypotensive activities of Epitizide.Approved, Vet Approved
ProcaterolProcaterol may increase the hypokalemic activities of Epitizide.Approved, Investigational
ProcyclidineThe serum concentration of Epitizide can be increased when it is combined with Procyclidine.Approved
ProglumetacinThe therapeutic efficacy of Epitizide can be decreased when used in combination with Proglumetacin.Experimental
PropacetamolThe therapeutic efficacy of Epitizide can be decreased when used in combination with Propacetamol.Approved, Investigational
PropanthelineThe serum concentration of Epitizide can be increased when it is combined with Propantheline.Approved
PropiverineThe serum concentration of Epitizide can be increased when it is combined with Propiverine.Approved, Investigational
PropyphenazoneThe therapeutic efficacy of Epitizide can be decreased when used in combination with Propyphenazone.Experimental
ProquazoneThe therapeutic efficacy of Epitizide can be decreased when used in combination with Proquazone.Experimental
ProscillaridinThe risk or severity of adverse effects can be increased when Epitizide is combined with Proscillaridin.Experimental
ProtokylolProtokylol may increase the hypokalemic activities of Epitizide.Approved, Vet Approved
PTC299The therapeutic efficacy of Epitizide can be decreased when used in combination with PTC299.Investigational
QuinaprilThe risk or severity of hypotension can be increased when Epitizide is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Epitizide can be increased when it is combined with Quinidine.Approved, Investigational
RacepinephrineRacepinephrine may increase the hypokalemic activities of Epitizide.Approved
RamiprilThe risk or severity of hypotension can be increased when Epitizide is combined with Ramipril.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Epitizide.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Epitizide.Approved, Investigational
RescinnamineThe risk or severity of hypotension can be increased when Epitizide is combined with Rescinnamine.Approved
ResveratrolThe therapeutic efficacy of Epitizide can be decreased when used in combination with Resveratrol.Approved, Experimental, Investigational
RimexoloneRimexolone may increase the hypokalemic activities of Epitizide.Approved
RitodrineRitodrine may increase the hypokalemic activities of Epitizide.Approved, Investigational
RofecoxibThe therapeutic efficacy of Epitizide can be decreased when used in combination with Rofecoxib.Approved, Investigational, Withdrawn
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Epitizide.Approved, Investigational
SalbutamolSalbutamol may increase the hypokalemic activities of Epitizide.Approved, Vet Approved
SalicylamideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Epitizide can be decreased when used in combination with Salicylic acid.Approved, Investigational, Vet Approved
SalmeterolSalmeterol may increase the hypokalemic activities of Epitizide.Approved
SalsalateThe therapeutic efficacy of Epitizide can be decreased when used in combination with Salsalate.Approved
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Epitizide.Approved
ScopolamineThe serum concentration of Epitizide can be increased when it is combined with Scopolamine.Approved, Investigational
SecobarbitalSecobarbital may increase the orthostatic hypotensive activities of Epitizide.Approved, Vet Approved
SemapimodThe therapeutic efficacy of Epitizide can be decreased when used in combination with Semapimod.Investigational
SeocalcitolThe risk or severity of hyperkalemia can be increased when Seocalcitol is combined with Epitizide.Experimental, Investigational
SeratrodastThe therapeutic efficacy of Epitizide can be decreased when used in combination with Seratrodast.Approved
SerrapeptaseThe therapeutic efficacy of Epitizide can be decreased when used in combination with Serrapeptase.Investigational
SertralineSertraline may increase the hyponatremic activities of Epitizide.Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Epitizide.Approved, Investigational
Sodium phosphateEpitizide may increase the nephrotoxic activities of Sodium phosphate.Approved
SolifenacinThe serum concentration of Epitizide can be increased when it is combined with Solifenacin.Approved
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Epitizide.Investigational
SpiraprilThe risk or severity of hypotension can be increased when Epitizide is combined with Spirapril.Approved
SRT501The therapeutic efficacy of Epitizide can be decreased when used in combination with SRT501.Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Epitizide.Approved, Investigational
SulfasalazineThe therapeutic efficacy of Epitizide can be decreased when used in combination with Sulfasalazine.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Epitizide.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Epitizide is combined with Sulpiride.Approved, Investigational
SuprofenThe therapeutic efficacy of Epitizide can be decreased when used in combination with Suprofen.Approved, Withdrawn
SuxibuzoneThe therapeutic efficacy of Epitizide can be decreased when used in combination with Suxibuzone.Experimental
TacalcitolThe risk or severity of hyperkalemia can be increased when Tacalcitol is combined with Epitizide.Experimental, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Epitizide.Approved
TarenflurbilThe therapeutic efficacy of Epitizide can be decreased when used in combination with Tarenflurbil.Investigational
TemocaprilThe risk or severity of hypotension can be increased when Epitizide is combined with Temocapril.Experimental, Investigational
TenidapThe therapeutic efficacy of Epitizide can be decreased when used in combination with Tenidap.Experimental
TenoxicamThe therapeutic efficacy of Epitizide can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Epitizide can be decreased when used in combination with Tepoxalin.Vet Approved
TerbutalineTerbutaline may increase the hypokalemic activities of Epitizide.Approved
TeriflunomideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Teriflunomide.Approved
ThiamylalThiamylal may increase the orthostatic hypotensive activities of Epitizide.Approved, Vet Approved
ThiopentalThiopental may increase the orthostatic hypotensive activities of Epitizide.Approved, Vet Approved
Tiaprofenic acidThe therapeutic efficacy of Epitizide can be decreased when used in combination with Tiaprofenic acid.Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Epitizide.Experimental
TinoridineThe therapeutic efficacy of Epitizide can be decreased when used in combination with Tinoridine.Investigational
TiotropiumThe serum concentration of Epitizide can be increased when it is combined with Tiotropium.Approved
TixocortolTixocortol may increase the hypokalemic activities of Epitizide.Approved, Withdrawn
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Epitizide.Approved, Investigational
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Epitizide.Approved, Investigational
Tolfenamic AcidThe therapeutic efficacy of Epitizide can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
TolmetinThe therapeutic efficacy of Epitizide can be decreased when used in combination with Tolmetin.Approved
TolterodineThe serum concentration of Epitizide can be increased when it is combined with Tolterodine.Approved, Investigational
ToremifeneEpitizide may increase the hypercalcemic activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Epitizide.Approved, Investigational
TrandolaprilThe risk or severity of hypotension can be increased when Epitizide is combined with Trandolapril.Approved
TranilastThe therapeutic efficacy of Epitizide can be decreased when used in combination with Tranilast.Approved, Investigational
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Epitizide.Approved, Vet Approved
TribenosideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Tribenoside.Experimental
TrihexyphenidylThe serum concentration of Epitizide can be increased when it is combined with Trihexyphenidyl.Approved
TrimethaphanThe serum concentration of Epitizide can be increased when it is combined with Trimethaphan.Approved, Investigational
TriptolideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Triptolide.Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Epitizide.Investigational, Withdrawn
TropatepineThe serum concentration of Epitizide can be increased when it is combined with Tropatepine.Experimental
TropicamideThe serum concentration of Epitizide can be increased when it is combined with Tropicamide.Approved, Investigational
TrospiumThe serum concentration of Epitizide can be increased when it is combined with Trospium.Approved
TubocurarineThe serum concentration of Epitizide can be increased when it is combined with Tubocurarine.Approved
UlobetasolUlobetasol may increase the hypokalemic activities of Epitizide.Approved
UmeclidiniumThe serum concentration of Epitizide can be increased when it is combined with Umeclidinium.Approved
ValdecoxibThe therapeutic efficacy of Epitizide can be decreased when used in combination with Valdecoxib.Approved, Investigational, Withdrawn
VecuroniumThe serum concentration of Epitizide can be increased when it is combined with Vecuronium.Approved
VenlafaxineVenlafaxine may increase the hyponatremic activities of Epitizide.Approved
VilanterolVilanterol may increase the hypokalemic activities of Epitizide.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Epitizide.Approved, Investigational
Vitamin DThe risk or severity of hyperkalemia can be increased when Vitamin D is combined with Epitizide.Approved, Nutraceutical, Vet Approved
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Epitizide.Approved, Investigational
ZaltoprofenThe therapeutic efficacy of Epitizide can be decreased when used in combination with Zaltoprofen.Approved, Investigational
ZileutonThe therapeutic efficacy of Epitizide can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the hyponatremic activities of Epitizide.Withdrawn
ZofenoprilThe risk or severity of hypotension can be increased when Epitizide is combined with Zofenopril.Experimental
ZomepiracThe therapeutic efficacy of Epitizide can be decreased when used in combination with Zomepirac.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
14906
ChEBI
135688
ChEMBL
CHEMBL2104605
Wikipedia
Epitizide
ATC Codes
C03EA03 — Epitizide and potassium-sparing agents

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.346 mg/mLALOGPS
logP1.22ALOGPS
logP0.88ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)9.05ChemAxon
pKa (Strongest Basic)-3.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area118.36 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity85.62 m3·mol-1ChemAxon
Polarizability35.67 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on February 16, 2018 13:23 / Updated on March 02, 2018 04:33